Want to see IN:AJANTPHARM full AI Analyst Report?
Top Page
Ajanta Pharma Limited
(AJANTPHARM)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹3,909.00
▲(16.12% Upside)
Action:Reiterated
Date:08/09/26
The score is driven primarily by strong underlying financial quality (solid growth and profitability with a very conservative balance sheet), partially offset by weaker FY2026 cash-flow conversion and some margin compression. Technicals add support due to a clear uptrend and constructive momentum, while valuation is the main headwind given the high P/E and modest dividend yield.
Positive Factors
Steady revenue growth and profitability
Sustained revenue expansion alongside strong net and operating margins indicates solid product demand, pricing capability and cost control. This supports durable earnings quality, provided the company can stabilize the recent margin decline.
Negative Factors
Recent margin compression
The margin decline may reflect unfavorable product mix, pricing pressure or higher input costs. If persistent, it could reduce operating leverage and weaken earnings growth even if revenue continues expanding, making margin recovery important for durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth and profitability
Sustained revenue expansion alongside strong net and operating margins indicates solid product demand, pricing capability and cost control. This supports durable earnings quality, provided the company can stabilize the recent margin decline.
Read all positive factors
Ajanta Pharma Limited (AJANTPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹442.26B
Dividend Yield1.71%
Average Volume (3M)9.18K
Price to Earnings (P/E)38.7
Beta (1Y)0.45
Revenue Growth20.19%
EPS Growth22.01%
CountryIN
Employees10,421
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)90.84
Shares Outstanding124,959,020
10 Day Avg. Volume4,276
30 Day Avg. Volume9,184
Financial Highlights & Ratios
PEG Ratio2.23
Price to Book (P/B)7.74
Price to Sales (P/S)6.43
P/FCF Ratio231.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)100.21
Revenue Forecast (FY)₹62.86B
Ajanta Pharma Limited Business Overview & Revenue Model
Company Description
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of ...
How the Company Makes Money
Ajanta Pharma makes money primarily by selling pharmaceutical formulations (finished dosage medicines such as tablets, capsules, creams/ointments, and eye/ear drops) under its own brands and product portfolios. Its key revenue streams generally in...
Ajanta Pharma Limited Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.76B | 54.53B | 45.88B | 41.62B | 37.08B | 32.84B |
| Gross Profit | 37.55B | 28.05B | 34.60B | 30.46B | 25.91B | 23.97B |
| EBITDA | 16.43B | 15.67B | 13.54B | 12.57B | 8.81B | 10.44B |
| Net Income | 11.35B | 10.56B | 9.20B | 8.16B | 5.88B | 7.13B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 61.55B | 50.15B | 46.38B | 46.79B | 40.56B |
| Cash, Cash Equivalents and Short-Term Investments | 6.65B | 6.65B | 6.15B | 4.60B | 8.44B | 3.28B |
| Total Debt | 0.00 | 2.60B | 474.20M | 352.80M | 356.30M | 250.30M |
| Total Liabilities | -45.27B | 16.28B | 12.25B | 10.71B | 12.91B | 7.91B |
| Stockholders Equity | 45.27B | 45.27B | 37.90B | 35.67B | 33.88B | 32.64B |
Cash Flow | ||||||
| Free Cash Flow | 1.10B | 1.51B | 8.39B | 6.33B | 6.17B | 4.13B |
| Operating Cash Flow | 2.84B | 5.16B | 11.57B | 7.85B | 7.92B | 5.62B |
| Investing Cash Flow | -5.49B | -4.29B | -3.77B | 653.90M | -5.60B | -741.00M |
| Financing Cash Flow | 1.82B | -1.55B | -7.33B | -10.51B | -1.08B | -4.60B |
Ajanta Pharma Limited Technical Analysis
Positive
3366.45
Price Trends
3474.98
Positive
3245.40
Positive
3004.34
Positive
Market Momentum
12.88
Positive
51.13
Neutral
51.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJANTPHARM, the sentiment is Positive. The current price of 3366.45 is below the 20-day moving average (MA) of 3586.03, below the 50-day MA of 3474.98, and above the 200-day MA of 3004.34, indicating a neutral trend. The MACD of 12.88 indicates Positive momentum. The RSI at 51.13 is Neutral, neither overbought nor oversold. The STOCH value of 51.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AJANTPHARM.
Ajanta Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹442.26B | 38.75 | ― | 1.71% | 20.19% | 22.01% | |
71 Outperform | ₹498.11B | 38.17 | ― | 0.30% | 10.59% | 68.21% | |
69 Neutral | ₹363.31B | 36.79 | ― | 0.18% | 18.36% | 35.60% | |
66 Neutral | ₹688.50B | 37.91 | ― | 0.21% | 32.94% | 138.54% | |
58 Neutral | ₹365.84B | 88.26 | ― | 1.27% | 18.37% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:AJANTPHARM
Ajanta Pharma Limited
3,516.75
995.20
39.47%
IN:EMCURE
Emcure Pharmaceuticals Limited
1,961.80
586.97
42.69%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,417.00
297.32
14.03%
IN:IPCALAB
IPCA Laboratories Limited
1,970.10
662.39
50.65%
IN:WOCKPHARMA
Wockhardt Limited
2,219.90
691.85
45.28%
Ajanta Pharma Limited Corporate Events
Ajanta Pharma Publishes June-Quarter Results in Mumbai Dailies for SEBI Compliance
Jul 31, 2026
Ajanta Pharma Limited has reported that its financial results for the quarter ended 30 June 2026 have been published in leading Mumbai newspapers, Business Standard and Navakal, to comply with Regulation 47 of the SEBI Listing Obligations and Disc...
Ajanta Pharma Sets July 2026 Virtual AGM, Releases FY 2025-26 Reports
Jun 18, 2026
Ajanta Pharma has scheduled its forty-seventh Annual General Meeting for July 16, 2026, to be conducted via video conferencing and other audio-visual means, reflecting continued use of virtual formats for shareholder engagement. In line with regul...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.